InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,319.26
(
-0.04%
)
US TECH 100
18,261.60
(
0.16%
)
Dow Jones
39,835.85
(
-0.09%
)
Brent Oil
82.28
(
-0.21%
)
Bitcoin
70,377.50
(
0.35%
)
Post# of 251894
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 179081

Wednesday, 06/11/2014 5:30:07 AM

Wednesday, June 11, 2014 5:30:07 AM

Post# of 251894
Novartis advanced their 2nd gen siponimod to phase III in SPMS not RRMS, so I will leave it out for now. As for the others, ponesimod also has some activity at S1P3 and that should be bad from the AE angle. Ceralifimod has the same activity at S1P1 and S1P5 that should help with efficacy but the price is in safety. My guess is the better choice is to target S1P1 mainly, as did Receptos and GSK (but GSK did not move their candidate beyond phase I, which implies they have seen unwanted AE).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up